Nuclear Medicine Imaging in Neuroblastoma: Current Status and New Developments

Atia Samim, Godelieve A M Tytgat, Gitta Bleeker, Sylvia T M Wenker, Kristell L S Chatalic, Alex J Poot, Nelleke Tolboom, Max M van Noesel, Marnix G E H Lam, Bart de Keizer

Onderzoeksoutput: Bijdrage aan tijdschriftArtikel recenserenpeer review

27 Citaten (Scopus)


Neuroblastoma is the most common extracranial solid malignancy in children. At diagnosis, approximately 50% of patients present with metastatic disease. These patients are at high risk for refractory or recurrent disease, which conveys a very poor prognosis. During the past decades, nuclear medicine has been essential for the staging and response assessment of neuroblastoma. Currently, the standard nuclear imaging technique is meta-[123I]iodobenzylguanidine ([123I]mIBG) whole-body scintigraphy, usually combined with single-photon emission computed tomography with computed tomography (SPECT-CT). Nevertheless, 10% of neuroblastomas are mIBG non-avid and [123I]mIBG imaging has relatively low spatial resolution, resulting in limited sensitivity for smaller lesions. More accurate methods to assess full disease extent are needed in order to optimize treatment strategies. Advances in nuclear medicine have led to the introduction of radiotracers compatible for positron emission tomography (PET) imaging in neuroblastoma, such as [124I]mIBG, [18F]mFBG, [18F]FDG, [68Ga]Ga-DOTA peptides, [18F]F-DOPA, and [11C]mHED. PET has multiple advantages over SPECT, including a superior resolution and whole-body tomographic range. This article reviews the use, characteristics, diagnostic accuracy, advantages, and limitations of current and new tracers for nuclear medicine imaging in neuroblastoma.

Originele taal-2Engels
TijdschriftJournal of personalized medicine
Nummer van het tijdschrift4
StatusGepubliceerd - 4 apr. 2021


Duik in de onderzoeksthema's van 'Nuclear Medicine Imaging in Neuroblastoma: Current Status and New Developments'. Samen vormen ze een unieke vingerafdruk.

Citeer dit